PT  - JOURNAL ARTICLE
AU  - Naveca, Felipe Gomes
AU  - Nascimento, Valdinete Alves
AU  - Nascimento, Fernanda
AU  - Ogrzewalska, Maria
AU  - Pauvolid-Corrêa, Alex
AU  - Araujo, Mia Ferreira
AU  - Arantes, Ighor
AU  - Rocha Batista, Érika Lopes
AU  - Álvares Magalhães, Alessandro Leonardo
AU  - Vinhal, Fernando
AU  - Mattos, Tirza Peixoto
AU  - Riediger, Irina
AU  - Carmo Debur, Maria do
AU  - Grinsztejn, Beatriz
AU  - Veloso, Valdiléa G
AU  - Brasil, Patricia
AU  - Rodrigues, Rodrigo Ribeiro
AU  - Rovaris, Darcita Buerger
AU  - Fernandes, Sandra Bianchini
AU  - Fernandes, Cristiano
AU  - Abdalla Santos, João Hugo
AU  - Abdalla, Lígia Fernandes
AU  - Costa-Filho, Rubens
AU  - Silva, Marineide
AU  - Souza, Victor
AU  - Costa, Ágatha Araújo
AU  - Mejía, Matilde
AU  - Brandão, Maria Júlia
AU  - Gonçalves, Luciana Fé
AU  - Silva, George Allan
AU  - de Jesus, Michele Silva
AU  - Pessoa, Karina
AU  - Guerra Corado, André de Lima
AU  - Gomes Duarte, Debora Camila
AU  - Machado, Ana Beatriz
AU  - de Azevedo Zukeram, Ketiuce
AU  - Valente, Natalia
AU  - Lopes, Renata Serrano
AU  - Pereira, Elisa Cavalcante
AU  - Appolinario, Luciana Reis
AU  - Rocha, Alice Sampaio
AU  - Lopez Tort, Luis Fernando
AU  - Sekizuka, Tsuyoshi
AU  - Itokawa, Kentaro
AU  - Hashino, Masanori
AU  - Kuroda, Makoto
AU  - Wallau, Gabriel Luz
AU  - Delatorre, Edson
AU  - Gräf, Tiago
AU  - Siqueira, Marilda Mendonça
AU  - Bello, Gonzalo
AU  - Resende, Paola Cristina
TI  - A case series of SARS-CoV-2 reinfections caused by the variant of concern Gamma in Brazil
AID  - 10.1101/2021.11.29.21266109
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.29.21266109
4099  - http://medrxiv.org/content/early/2021/11/29/2021.11.29.21266109.short
4100  - http://medrxiv.org/content/early/2021/11/29/2021.11.29.21266109.full
AB  - The rapid spread of the SARS-CoV-2 Variant of Concern (VOC) Gamma during late 2020 and early 2021 in Brazilian settings with high seroprevalence raised some concern about the potential role of reinfections in driving the epidemic. Very few cases of reinfection associated with the VOC Gamma, however, have been reported. Here we describe 25 cases of SARS-CoV-2 reinfection confirmed by real-time RT-PCR twice within months apart in Brazil. SARS-CoV-2 genomic analysis confirmed that individuals were primo-infected between March and December 2020 with distinct viral lineages, including B.1.1, B.1.1.28, B.1.1.33, B.1.195 and P.2, and then reinfected with the VOC Gamma between 3 to 12 months after primo-infection. The overall mean cycle threshold (Ct) value of the first (25.7) and second (24.5) episodes were roughly similar for the whole group and 14 individuals displayed mean Ct values < 25.0 at reinfection. Sera of 14 patients tested by plaque reduction neutralization test after reinfection displayed detectable neutralizing antibodies against Gamma and other SARS-CoV-2 variants (B.1.33, B.1.1.28 and Delta). All individuals have milder or no symptoms after reinfection and none required hospitalization. The present study demonstrates that the VOC Gamma was associated with reinfections during the second Brazilian epidemic wave in 2021 and raised concern about the potential infectiousness of reinfected subjects. Although individuals here analyzed failed to mount a long-term sterilizing immunity, they developed a high anti-Gamma neutralizing antibody response after reinfection that may provide some protection against severe disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding support from Department of Science and Technology (DECIT), Ministry of Health, CGLab/MoH (General Laboratories Coordination of Brazilian Ministry of Health), CVSLR/FIOCRUZ (Coordination of Health Surveillance and Reference Laboratories of Oswaldo Cruz Foundation), CNPq COVID-19 MCTI 402457/2020-0 and 403276/2020-9; INOVA Fiocruz VPPCB-005-FIO-20-2 and VPPCB-007-FIO-18-2-30; FAPERJ: E26/210.196/2020; FAPEAM (PCTI-EmergeSaude/AM call 005/2020 and Rede Genomica de Vigilancia em Saude - REGESAM). This study was also supported by a Grant-in Aid from the Japan Agency for Medical Research and Development (AMED) under Grant number JP20fk0108103.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Amazonas State University (CAAE: 25430719.6.0000.5016) and by the Ethics Committee of the FIOCRUZ (CAAE: 68118417.6.0000.5248).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe consensus SARS-CoV-2 sequences generated in this work are available online at EpiCoV database in GISAID https://www.gisaid.org under the accession numbers: EPI_ISL_811148, EPI_ISL_811149, EPI_ISL_1034304 to 1034306, EPI_ISL_1114151, EPI_ISL_1534003, EPI_ISL_2017281 to 2017324, EPI_ISL_2017449, EPI_ISL_2187985, EPI_ISL_2187989, EPI_ISL_2187990, EPI_ISL_2188000, EPI_ISL_2196249 to 2196252, EPI_ISL_2196357, EPI_ISL_2196360 to 2196362, EPI_ISL_2227564, EPI_ISL_2497433 to 2497435, EPI_ISL_2497440, EPI_ISL_2497459, EPI_ISL_2497469, EPI_ISL_2617626, EPI_ISL_2617627, EPI_ISL_2645521, EPI_ISL_2921603 to 2921609, EPI_ISL_3061879, EPI_ISL_3061892, EPI_ISL_3061893, EPI_ISL_3061900 to 3061902, EPI_ISL_3087898, EPI_ISL_4563059 and EPI_ISL_4563061.